

## **Biographical Sketch for Harsha Murthy**

Harsha Murthy is a senior financial and pharmaceuticals/biotech executive with extensive experience in operations, finance, strategic planning, business development and licensing in a variety of corporate settings. Mr. Murthy currently is managing partner of Consummate Capital LLC, a New York City-based investment and advisory firm that sources and structures the acquisition of generic and branded pharmaceutical products for its clients. Mr. Murthy most recently served as co-founder and managing partner of Konanda Pharma Partners, a New York City-based private equity fund that invested in branded and marketed specialty pharmaceutical products and built portfolio companies to make and market those drug products. At Konanda, Mr. Murthy led the acquisition of major products from “Big Pharma” companies such as Roche and Shire and formed multiple portfolio companies (including hiring operating management) to market and grow the pharmaceutical assets Konanda acquired. Prior to founding Konanda, Mr. Murthy served as Executive Vice President and Corporate Head- Strategic Planning and Business Development for King Pharmaceuticals, Inc., a vertically integrated branded pharmaceuticals company with over \$1 billion in annual revenues, listed on the New York Stock Exchange (KG) and which is a S&P 500 Index company. Mr. Murthy was responsible for all of King’s mergers, acquisitions, in-licensing, partnership and investment banking relationships. In this capacity at King, Mr. Murthy identified, led and closed a number of significant transactions including King’s strategic partnerships with Palatin Technologies and Pain Therapeutics, divestitures of several of King’s late-stage products, and acquisitions of product rights from “Big Pharma” across a number of therapeutic areas.

Prior to joining King, Mr. Murthy was Vice President-Business Strategy and Administration at Eyetech Pharmaceuticals, Inc., a biopharmaceutical company focused on eye disease that makes and markets Macugen®, a product for age-related macular degeneration, one of the leading causes of blindness. At Eyetech, Mr. Murthy had management responsibilities for Eyetech’s manufacturing, business development, licensing, human resources, legal, third party consultant, website and various other operational activities and worked as a member of the company’s senior management team leading its major clinical, financing and partnership initiatives, including the company’s three financing rounds that raised in excess of \$150 million and its historic strategic partnership with Pfizer. One of the biotech industry’s most successful stories, Eyetech was founded in 2000; went public in 2004; received FDA approval of Macugen® in 2005; and was acquired by OSI Pharmaceuticals in late 2005 for nearly \$1 billion.

Mr. Murthy has worked in a number of private sector business and legal capacities as well as in the government over the years, including as:

- Managing Director of GE Capital in its international equity investment activities in Asia, South America, Africa, Europe and the United States;
- Advisor to the Chairman and Commissioners of the U.S. Securities and Exchange Commission;
- Venture capital advisory board member and consultant to a number of technology companies (including Agility Ventures (an internet incubator); Mallen Technologies (an engine development company); kRoad Ventures (an alternative energy fund); and Nordic Wind (wind turbine development)); and
- Corporate and securities lawyer with the firms of Davis Polk & Wardwell and Latham & Watkins, each in New York City.

Mr. Murthy has extensive relationships in the healthcare and venture capital investment communities as well as among pharmaceutical and biotech companies. He has been called upon

to offer strategic advice to leaders of U.S.- and overseas-based young and mature companies as they seek to raise funds, identify partners, advance clinical programs, build operating teams, obtain regulatory approvals and acquire and commercialize branded and generic products.

He currently serves and has served on a number of corporate and not-for-profit boards of directors, including those of Validus Pharmaceuticals, Inc. (psychiatry/neuroscience company); Fontus Pharmaceuticals, Inc. (nephrology/acute care company); Electrolux Corporation (vacuum cleaner manufacturer); Duke University Libraries (Board chair); the Asian American Justice Center (Executive Committee); CorbinDances (Board chair); the Asian American Legal Defense and Education Fund (chair emeritus), Circle Networks; Agility Ventures (technology venture capital advisory board); the Wellmont [Hospital] Foundation; the Aplastic Anemia and MDS International Foundation (bone marrow disease foundation); and CLT International (an international education and development organization focused on India). He has been active with a number of artistic (dance and music), philanthropic and charitable groups in the U.S. and overseas, including Battery Dance Company of New York (chair emeritus); Chamber Dance Project (Executive Committee member); Rioult (Chairman's Council chair); and CorbinDances (Board chair).

Mr. Murthy has also lectured widely on international business and pharmaceutical topics before business, government and professional groups and at colleges and universities, including audiences at the U.S. State Department's Foreign Service College, Harvard, Princeton, Yale and Georgetown. Born in New Delhi, India of Indian parents, Mr. Murthy was raised in Ohio. He received a B.A. degree summa cum laude from Duke University (where he was the Commencement Speaker and a member of Phi Beta Kappa) and a J.D. from Stanford Law School (where he was a managing editor of the Stanford Law Review). He completed additional course work at Harvard College and Oxford University (New College).

[Ω-END]

---